Gilead Sciences Announces Executive Promotions
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients. The company also announced that Diana Brainard, MD, has been promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng, MD, PhD, Chief Medical Officer, has decided to leave Gilead to pursue another opportunity.
Mr. Alton joined the company nearly 20 years ago and was the architect of its access program, which has enabled Gilead’s HIV medicines to reach more than 11 million people in the developing world. He has helped shape the organization in a number of executive positions, including as general counsel, and more recently, leading the company’s international commercial operations and corporate affairs groups. Prior to joining Gilead, he was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships, and corporate finance transactions for healthcare and information technology companies. Mr. Alton received a bachelor's degree from the University of California, Berkeley, and holds a JD from Stanford University.
“Gregg has a deep and broad understanding of the company and an unparalleled commitment to enabling access to our medicines for millions of people in both the developed and developing world,” said John F. Milligan, PhD, President and Chief Executive Officer of Gilead. “Bringing together into one organization a number of groups – including Access Operations & Emerging Markets, Public Affairs & Advocacy, Government Affairs, Medical Affairs, Digital Patient Solutions and the company’s commercial operations in certain countries in Asia – will help us better serve patients.”
Dr. Brainard joined Gilead in 2010. She has extensive training and experience in immunology, infectious diseases and drug development. Under her leadership, Gilead received regulatory approval of four chronic hepatitis C virus (HCV) therapies in a period of less than four years. She was promoted to Vice President, Clinical Research, Liver Diseases, in 2015. Dr. Brainard received a bachelor’s degree from Brown University, holds an MD from Tulane University School of Medicine, and completed her residency and fellowship in internal medicine and infectious diseases at Harvard University. Dr. Brainard trained as an infectious diseases physician at Massachusetts General Hospital and was on faculty at Harvard Medical School, where her NIH-funded research focused on translational models and T-cell trafficking in HIV infection. In addition to her clinical and research activities in Boston, she helped establish an immunology laboratory and train researchers at the Nelson R Mandela School of Medicine, University of KwaZulu-Natal in Durban, South Africa.
“Diana is an astute, knowledgeable and experienced clinician and researcher with broad expertise across the field of infectious diseases. She played an instrumental role in the rapid clinical development and approval of Gilead’s HCV medicines,” said John McHutchison, MD, Chief Scientific Officer and Head of Research and Development. “The vision and leadership that she brings to this role will enable Gilead to continue to innovate, and advance new therapies for people with HIV and other emerging viruses.”
Dr. Cheng joined Gilead in 1999 to lead the company’s development-stage programs in HIV/AIDS. He received additional responsibility for the company’s Development Operations organization in 2009 and was named Executive Vice President in 2015. Dr. Cheng was appointed Chief Medical Officer in March.
“During his time at Gilead, Andrew played a definitive role in bringing forward new medicines that transformed the lives of millions of people with serious illnesses,” said Dr. Milligan. “Andrew played an especially critical part in advancing our portfolio of HIV products, and we’re extremely grateful for his many contributions and wish him all the best in the future. We are very pleased that Diana will lead this important therapeutic area for us going forward, as we seek to advance our next generation of HIV medicines, including potential options for prevention and perhaps one day a cure.”
Dr. Cheng will remain at Gilead until September 7 to help with the transition of his duties. Mr. Alton and Dr. Brainard will take on their new roles effective immediately.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties, and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Amy Flood, 650-522-5643
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Prominent Coalition of World Class International and Danish Law Firms and ISAF Management Company Proceed with Investor Lawsuit against Danske Bank20.11.2018 23:00 | Pressemelding
International Securities Associations and Foundations Management Company (“ISAF”) announces the formation of an international coalition of leading American, German and Dutch law firms and the appointment of the preeminent Danish law firm, Németh Sigetty, to proceed with a lawsuit against Danske Bank A/S (“Danske” or the “Bank”) to pursue compensation for damaged investors after revelations of money laundering, financial mismanagement and deficient regulatory disclosures. The lawsuit will be filed in Copenhagen, Denmark on behalf of investors who suffered investment losses in Danske’s share price after various disclosures related to an estimated EUR €200 billion money transfer scheme involving non-resident Eastern European and Russian customers in the Bank’s Estonian Branch. Information about critical lapses in Danske’s ‘know your customer’ and anti-money laundering internal enforcement policies, and its failure to act upon both internal and external warnings of non-compliance, caused a
Saif bin Zayed Witnesses Endorsement of Abu Dhabi Declaration by Religious Leaders at Wahat Al Karama20.11.2018 22:28 | Pressemelding
Under the patronage of His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, Lt. General HH Sheikh Saif bin Zayed Al Nahyan, Deputy Prime Minister and Minister of Interior, attended the endorsement of the “Abu Dhabi Declaration.” The declaration, issued by the Interfaith Alliance for Safer Communities: Child Dignity in the Digital World Forum was endorsed and approved by religious and spiritual leaders participating in the two-day assembly, which took place in Abu Dhabi on November 19-20, who pledged to act upon the declaration’s articles and achieve the objectives and obligations outlined by the leaders of the seven major world religions participating in the forum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005775/en/ Saif bin Zayed, Khalifa bin Tahnoun, alongside religious and spiritual leaders in front of a memorial to express commitment
Guy Carpenter Names Ross Howard Vice Chairman20.11.2018 17:46 | Pressemelding
Guy Carpenter & Company, LLC, a leading global risk and reinsurance specialist and a wholly owned subsidiary of Marsh & McLennan Companies (NYSE: MMC), today announced a new leadership appointment from the Jardine Lloyd Thompson Group plc (JLT) reinsurance organization. Effective upon closing of the transaction between Guy Carpenter’s parent company, Marsh & McLennan Companies and JLT, which remains subject to the receipt of certain antitrust and financial regulatory approvals, Ross Howard, Chairman of JLT Re, will become Vice Chairman of Guy Carpenter, reporting to President & CEO Peter Hearn. Mr. Howard will also become a member of Guy Carpenter’s Executive Committee and will be responsible for developing new business opportunities and assisting with client relationships in order to continue the growth of the combined global reinsurance business. Additionally, Mr. Howard will also play a key role in executing the integration of JLT Re with Guy Carpenter. “We are very excited to take
IDEMIA Will Present Its 2018 Quarterly Financial Results to Investors on November 21, 201820.11.2018 17:31 | Pressemelding
IDEMIA, the world leader in Augmented Identity, today announced that it will present its Q3 2018 financial results to investors on Wednesday November 21, 2018. Yann Delabrière (CEO), Frédéric Beylier (COO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 1:00 pm CET (12:00 pm London Time / 7:00 am New York Time). For more information, please refer to our website: http://investors.oberthur.com About IDEMIA OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable t
OCP Announces Date of Third Quarter 2018 Earnings20.11.2018 17:00 | Pressemelding
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter 2018 results on Thursday, November 29, 2018. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 8:30 a.m. EST, 2:30 p.m. Morocco time (GMT+1), and 1:30 p.m. London time (GMT). OCP senior management will host a conference call to discuss third quarter 2018 results at 9:30 a.m. EST, 3:30 p.m. Morocco time (GMT+1), and 2:30 p.m. London time (GMT) on Thursday, November 29, 2018 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing firstname.lastname@example.org About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. O
Arch Insurance Announces Strategic Leadership Changes20.11.2018 15:50 | Pressemelding
Arch Insurance (“Arch”) today announced Hugh Sturgess will assume the role of Chief Executive Officer, Arch Insurance International, effective Jan. 1, 2019, subject to regulatory approvals. Arch Insurance International includes Arch’s insurance operations in Europe, Bermuda and Australia. Mr. Sturgess has been with Arch Insurance since 2005 and is currently President and CEO of Arch Insurance Canada Ltd., where he has strategic and operational responsibility for a multi-line underwriting portfolio. Before joining Arch, Mr. Sturgess held various roles in the financial services industry, including tenures with the Royal Bank of Canada and Chubb Insurance Company of Canada. “Arch Insurance International underwrites a diverse portfolio of specialty insurance solutions across a number of geographies, with a key focus on providing value to our distribution partners and customers,” Mr. Sturgess said. “I look forward to the opportunity to work with our team in continuing to expand the value pr